Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2020
Nexplanon recommended after second submission
22 October 2020 - The first submission was withdrawn. ...
Posted by Michael Wonder on 22 Oct 2020
CADTH in favour of new indication for Soliris
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...
Posted by Michael Wonder on 22 Oct 2020
Patients, health organisations band together to bring breakthrough treatments to Canada sooner
21 October 2020 - Thirteen health charities and patient groups are calling on the Canadian government to improve access to ...
Posted by Michael Wonder on 21 Oct 2020
Canadian baby with spinal muscular atrophy to get ‘world’s most expensive drug’
20 October 2020 - A little over a year ago, the idea of raising US$2.125 million to receive the “world’s ...
Posted by Michael Wonder on 20 Oct 2020
Health charities and patient groups join together to protect access to breakthrough medical treatments in Canada
19 October 2020 - Patients shut out of process leading to the release of revised guidelines by the Patented Medicine Prices ...
Posted by Michael Wonder on 20 Oct 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis
19 October 2020 - Taltz is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA. ...
Posted by Michael Wonder on 19 Oct 2020
UCP approves policy to create private health care system in Alberta
18 October 2020 - Alberta’s United Conservative Party has voted to approve a policy that supports creating a “privately funded ...
Posted by Michael Wonder on 17 Oct 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma
15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...
Posted by Michael Wonder on 15 Oct 2020
Health Canada approves first-ever gene replacement therapy, Luxturna
15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease. ...
Posted by Michael Wonder on 13 Oct 2020
Moderna announces initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19 (mRNA-1273)
13 October 2020 - Confirmation underscores Moderna’s commitment to make its vaccine available in Canada. ...
Posted by Michael Wonder on 12 Oct 2020
Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours
8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...
Posted by Michael Wonder on 11 Oct 2020
Rapid qualitative evidence syntheses in health technology assessment: experiences, challenges, and lessons
9 October 2020 - Health care decision makers are increasingly demanding that health technology assessment is patient focused, and considers data ...
Posted by Michael Wonder on 10 Oct 2020
Health Canada approves Inqovi (decitabine and cedazuridine) oral therapy for two types of blood cancers, MDS and CMML
8 October 2020 - Oral drug can be taken at home, which may enable some patients to avoid some hospital visits. ...
Posted by Michael Wonder on 10 Oct 2020
Pfizer Canada and BioNTech initiate rolling submission to Health Canada for SARS-CoV-2 vaccine candidate BNT162b2
9 October 2020 - Pfizer Canada and BioNTech will continue regular and open dialogue with Health Canada providing results from their ...
Posted by Michael Wonder on 08 Oct 2020
Health Canada approves Zeposia, an oral treatment for relapsing remitting multiple sclerosis
7 October 2020 - Bristol Myers Squibb's medication provides a new oral treatment option for Canadians living with the neurological disease. ...